The "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT) randomized controlled trial: design and methods
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie
PubMed
28144914
DOI
10.1007/s40520-016-0715-2
PII: 10.1007/s40520-016-0715-2
Knihovny.cz E-zdroje
- Klíčová slova
- Disability, Functional impairment, Nutrition, Physical activity, Prevention, Unmet needs,
- MeSH
- analýza nákladů a výnosů MeSH
- cvičení * MeSH
- křehký senior * MeSH
- kvalita života MeSH
- lidé MeSH
- omezení pohyblivosti * MeSH
- sarkopenie prevence a kontrola terapie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stárnutí MeSH
- úrazy pádem prevence a kontrola MeSH
- výzkumný projekt MeSH
- Check Tag
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- multicentrická studie MeSH
- randomizované kontrolované studie MeSH
The sustainability of health and social care systems is threatened by a growing population of older persons with heterogeneous needs related to multimorbidity, frailty, and increased risk of functional impairment. Since disability is difficult to reverse in old age and is extremely burdensome for individuals and society, novel strategies should be devised to preserve adequate levels of function and independence in late life. The development of mobility disability, an early event in the disablement process, precedes and predicts more severe forms of inability. Its prevention is, therefore, critical to impede the transition to overt disability. For this reason, the Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies (SPRINTT) project is conducting a randomized controlled trial (RCT) to test a multicomponent intervention (MCI) specifically designed to prevent mobility disability in high-risk older persons. SPRINTT is a phase III, multicenter RCT aimed at comparing the efficacy of a MCI, based on long-term structured physical activity, nutritional counseling/dietary intervention, and an information and communication technology intervention, versus a healthy aging lifestyle education program designed to prevent mobility disability in 1500 older persons with physical frailty and sarcopenia who will be followed for up to 36 months. The primary outcome of the SPRINTT trial is mobility disability, operationalized as the inability to walk for 400 m within 15 min, without sitting, help of another person, or the use of a walker. Secondary outcomes include changes in muscle mass and strength, persistent mobility disability, falls and injurious falls, disability in activities of daily living, nutritional status, cognition, mood, the use of healthcare resources, cost-effectiveness analysis, quality of life, and mortality rate. SPRINTT results are expected to promote significant advancements in the management of frail older persons at high risk of disability from both clinical and regulatory perspectives. The findings are also projected to pave the way for major investments in the field of disability prevention in old age.
Clinics of Internal Medicine and Geriatrics Helsinki University Central Hospital Helsinki Finland
Department of Aging and Geriatric Research University of Florida Gainesville FL USA
Department of Epidemiology and Public Health CHU Toulouse Toulouse France
Department of Geriatrics 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Internal Medicine and Geriatrics University of Helsinki Helsinki Finland
Foundation for Diabetes Research in Older People Diabetes Frail Ltd Droitwich Spa UK
Geriatric Department University Hospital Ramón y Cajal Madrid Spain
Geriatrics and Geriatric Emergency Care IRCCS INRCA Ancona Italy
Gérontopôle Centre Hospitalier Universitaire de Toulouse Toulouse France
Global Translational Medicine Novartis Institutes for Biomedical Research Basel Switzerland
INSERM Toulouse University UMR1027 Toulouse France
Institute for Biomedicine of Aging Friedrich Alexander University Nuremberg Germany
Sanofi R and D Paris Chilly Mazarin France
Service of Geriatrics Getafe University Hospital Madrid Spain
Unit of General Practice Oulu University Hospital Oulu Finland
Citace poskytuje Crossref.org